The Sheinbaum government announced on Thursday an investment of 643.6 million dollars by four pharmaceutical companies, who add to the “Mexico Plan”, a comprehensive strategy of the federal government to transform the country’s economy through industrialization, innovation and social inclusion.
“What is presented today is a relevant investment around 12,000 million pesos (643.6 million dollars) (…) of the pharmaceutical sector of Mexico, which is a high priority for the president,” said the Secretary of Economy, Marcelo Ebrard, during the presidential press conference.
The official explained that health is a “high priority” for President Claudia Sheinbaum, not only because of the impact on the Mexican population, but also as “forecast” to be ready “for any pandemic or any circumstance.”
David Kershenovich, secretary of Health, explained that investments come from three multinational companies and a Mexican, which have an “important presence in the country”, in addition to being focused on expanding their productive, technological and export capacity.
“With these projects, innovation is encouraged, the manufacturing industry is strengthened, the clinical research and digitalization capacities of the processes are expanded and especially new highly specialized jobs are created by positioning Mexico as a regional leader in the pharmaceutical industry and medical devices,” he said.
Soser context: four pharmaceuticals will invest 560 MDD for medical ‘self -sufficiency’ in Mexico
These are the four pharmaceutical projects for Mexico
Juan Augusto Muench Castañeda, general director of the German Boehringer Ingelheim for Mexico, Central America and the Caribbean, announced that the company will make a multiannual investment of 3.5 billion pesos (187.45 million dollars), which will make its table of table production in Xochimilco, south of the Mexican capital, be the largest in the world.
This plant, which will be above manufacturing sites in Spain, China, Japan, Greece and Germany, expects to create direct employment for 1,800 collaborators and 15,000 indirect jobs.
“Our goal is that from Xochimilco, 5,000 million tablets are manufactured,” he said.
For his part, Edmundo Jimenez Luna, general director of the Mexican Laboratories Carnot, announced its expansion and noted that during the next 5 years 3,500 million pesos (187.45 million dollars) will be invested that will generate 600 direct jobs of high specialty, and at least 5,000 indirect.
The new plant will be located in Villas de Tezontepec, in the central state of Hidalgo, and will be a strategic center of pharmaceutical manufacturing and biotechnology with cutting -edge technology capable of exporting products to more than 30 countries.
Meanwhile, Manuel Bravo Pereyra, general director of the German Bayer in Mexico, said that his investment is aimed at health and food.
The investment will be 3,000 million pesos (160.68 million dollars) in the next 5 years, which will expand their ability to produce pharmaceutical active ingredients in its Orizaba plant, Veracruz, and production lines will be added for new medications in its Lerma plant, State of Mexico.
Finally, julio Ordaz, general director of the British Astrazeneca Mexico, announced an investment of more than 2,000 million pesos in 2 years, which will generate more than 600 specialized jobs and more than 6,500 indirect jobs.
At least 1.4 billion pesos (almost 75 million dollars) will go to clinical research, while the rest will be for innovation and technology and for the expansion of its manufacturing site in the State of Mexico.
With EFE information
Subscribe to Forbes Mexico
